<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03671967</url>
  </required_header>
  <id_info>
    <org_study_id>MOH_2018-12-25_004857</org_study_id>
    <nct_id>NCT03671967</nct_id>
  </id_info>
  <brief_title>PipEracillin Tazobactam Versus mERoPENem for Treatment of Bloodstream Infections Caused by Cephalosporin-resistant Enterobacteriaceae (PETERPEN)</brief_title>
  <acronym>PETERPEN</acronym>
  <official_title>Piperacillin Tazobactam Versus Meropenem for Treatment of Bloodstream Infections Caused by Cephalosporin-resistant Enterobacteriaceae- a Non-inferiority Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rambam Health Care Campus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Rabin Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Modena and Reggio Emilia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tel Aviv Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Meir Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Soroka University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Chaim Sheba Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>McGill University Health Centre/Research Institute of the McGill University Health Centre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jewish General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Canadian Institutes of Health Research (CIHR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Rambam Health Care Campus</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Data regarding optimal treatment for extended-spectrum beta-lactamase (ESBL) producing&#xD;
      Enterobacteriaceae blood-stream infection are lacking. Observational studies show conflicting&#xD;
      results when comparing treatment with combination beta-lactam-beta-lactamase inhibitor and&#xD;
      carbapenems. The investigators aim to evaluate the effect of definitive treatment with&#xD;
      meropenem vs. piperacillin-tazobactam on the outcome of patients with bacteremia due to&#xD;
      cephalosporin-non-susceptible Enterobacteriaceae. The investigators hypothesize that&#xD;
      piperacillin-tazobactam is non-inferior to meropenem.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2019</start_date>
  <completion_date type="Anticipated">April 2024</completion_date>
  <primary_completion_date type="Anticipated">January 2024</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>open-label randomized controlled trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>30 days from randomization</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment failure</measure>
    <time_frame>7 days from randomization</time_frame>
    <description>death OR fever &gt; 38°C in the last 48 hours OR lack of resolution of symptoms attributed to the focus of infection OR Sequential Failure Organ Assessment (SOFA) score increasing OR positive blood cultures by the time point assessed</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>14 and 90 days from randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment failure</measure>
    <time_frame>14 days and 30 days from randomization</time_frame>
    <description>death OR fever &gt; 38°C in the last 48 hours OR lack of resolution of symptoms attributed to the focus of infection OR Sequential Failure Organ Assessment (SOFA) score increasing OR positive blood cultures by the time point assessed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbiological failure</measure>
    <time_frame>7 days and 14 days from randomization</time_frame>
    <description>Repeat positive blood cultures with index pathogen on day 4 or later from randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrent positive blood cultures (relapse)</measure>
    <time_frame>30 days and 90 days from randomization</time_frame>
    <description>recurrent positive blood cultures with the index pathogen after prior sterilization of blood cultures or after end of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clostridium difficile associated diarrhea</measure>
    <time_frame>90 days from randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically or microbiologically documented infection other than Gram-negative bacteremia</measure>
    <time_frame>90 days from randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of hospital re-admissions</measure>
    <time_frame>90 days from randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of resistance</measure>
    <time_frame>90 days from randomization</time_frame>
    <description>clinical isolates resistant to piperacillin/tazobactam and meropenem and any carbapenem-resistant bacteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Carriage of carbapenemase-producing Enterobacteriaceae (CPE) and non-CPE carbapenem-resistant Enterobacteriaceae in-hospital</measure>
    <time_frame>90 days from randomization</time_frame>
    <description>detected by weekly rectal surveillance of carriage while in-hospital</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total in-hospital days</measure>
    <time_frame>30 days and 90 days from randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total antibiotic days</measure>
    <time_frame>30 days and 90 days from randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>30 days from randomization</time_frame>
    <description>diarrhea, liver function test abnormalities, antibiotic rash or other immediate-type allergy, acute kidney injury defined according to RIFLE criteria</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1084</enrollment>
  <condition>Beta Lactam Resistant Bacterial Infection</condition>
  <condition>Enterobacteriaceae Infections</condition>
  <condition>Bacteremia</condition>
  <arm_group>
    <arm_group_label>piperacillin tazobactam</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>meropenem</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Piperacillin/tazobactam</intervention_name>
    <description>4.5 grams QID</description>
    <arm_group_label>piperacillin tazobactam</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Meropenem</intervention_name>
    <description>1 gram TID</description>
    <arm_group_label>meropenem</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adults (age ≥ 18 years)&#xD;
&#xD;
          2. New onset BSI due to E. coli or Klebsiella spp. in one or more blood cultures&#xD;
             associated with evidence of infection.&#xD;
&#xD;
          3. The microorganism will have to be non-susceptible to third generation cephalosporins&#xD;
             (ceftriaxone and ceftazidime) and susceptible to both PTZ and meropenem (see&#xD;
             microbiological methods).&#xD;
&#xD;
          4. Both community and hospital-acquired bacteremias will be included.&#xD;
&#xD;
          5. We will permit the inclusion of bacteremias due to E. coli or Klebsiella spp. with&#xD;
             concomitant growth in blood of skin commensals considered as contaminants.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. More than 72 hr. elapsed since initial blood culture taken, regardless of the time&#xD;
             covering antibiotics were started (up to 72 hrs.).&#xD;
&#xD;
          2. Polymicrobial bacteremia. Polymicrobial bacteremia will be defined as either growth of&#xD;
             two or more different species of microorganisms in the same blood culture, or growth&#xD;
             of different species in two or more separate blood cultures within the same episode.&#xD;
&#xD;
          3. Patients with prior bacteremia or infection that have not completed antimicrobial&#xD;
             therapy for the previous infectious episode.&#xD;
&#xD;
          4. Patients with septic shock at the time of enrollment and randomization, defined as at&#xD;
             least 2 measurements of systolic blood pressure &lt; 90 mmHg and/or use of vasopressors&#xD;
             (dopamine&gt;15μg/kg/min, adrenalin&gt;0.1μg/kg/min, noradrenalin&gt;0.1μg/kg/min, vasopressin&#xD;
             any dose) in the 12 hours prior to randomization. In the absence of the use of&#xD;
             vasopressors, a systolic blood pressure &lt;90 would need to represent a deviation for&#xD;
             the patient's known normal blood pressure.&#xD;
&#xD;
          5. BSI due to specific infections known at the time of randomization:&#xD;
&#xD;
               1. Endocarditis / endovascular infections&#xD;
&#xD;
               2. Osteomyelitis (not resected)&#xD;
&#xD;
               3. Central nervous system infections&#xD;
&#xD;
          6. Allergy to any of the study drugs confirmed by history taken by the investigator&#xD;
&#xD;
          7. Previous enrollment in this trial&#xD;
&#xD;
          8. Concurrent participation in another interventional clinical trial&#xD;
&#xD;
          9. Imminent death (researcher's assessment of expected death within 48 hrs. of&#xD;
             recruitment)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roni Bitterman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rambam Health Care Campus</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mical Paul, MD</last_name>
    <role>Study Director</role>
    <affiliation>Rambam Health Care Campus</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Leonard Leibovici, MD</last_name>
    <role>Study Director</role>
    <affiliation>Rabin Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Cristina Mussini, MD</last_name>
    <role>Study Director</role>
    <affiliation>University of Modena and Reggio Emilia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Roni Bitterman, MD</last_name>
    <phone>972-4-7772991</phone>
    <email>ro_oren@rambam.health.gov.il</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mical Paul, MD</last_name>
    <phone>972-4-7772991</phone>
    <email>m_paul@rambam.health.gov.il</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>McGill University Health Centre</name>
      <address>
        <city>Montreal, Quebec</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Todd Lee, MD</last_name>
    </contact>
    <contact_backup>
      <email>todd.lee@mcgill.ca</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Rambam Health Care Campus</name>
      <address>
        <city>Haifa</city>
        <zip>3435306</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roni Bitterman</last_name>
      <phone>47772991</phone>
      <email>ro_oren@rambam.health.gov.il</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Israel</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 12, 2018</study_first_submitted>
  <study_first_submitted_qc>September 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 14, 2018</study_first_posted>
  <last_update_submitted>October 18, 2021</last_update_submitted>
  <last_update_submitted_qc>October 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rambam Health Care Campus</investigator_affiliation>
    <investigator_full_name>Roni Oren MD</investigator_full_name>
    <investigator_title>principal investigator</investigator_title>
  </responsible_party>
  <keyword>bacteremia</keyword>
  <keyword>enterobacteriaceae</keyword>
  <keyword>extended spectrum beta-lactamase</keyword>
  <keyword>meropenem</keyword>
  <keyword>piperacillin tazobactam</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Bacterial Infections</mesh_term>
    <mesh_term>Bacteremia</mesh_term>
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Enterobacteriaceae Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meropenem</mesh_term>
    <mesh_term>Tazobactam</mesh_term>
    <mesh_term>Piperacillin</mesh_term>
    <mesh_term>Piperacillin, Tazobactam Drug Combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified individual patient data collected during the trial will be made available for an unlimited time period following publication of trial results. Data will be available for researchers who provide a methodologically sound proposal and contingent on both the researchers' and our ethics committee approval and the signing of a data sharing agreement.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>following publication and for unlimited time</ipd_time_frame>
    <ipd_access_criteria>proposals should be sent to the principal investigator at ro_oren@rambam.health.gov.il</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

